Skip to main content

How does Lutathera work to treat gastroenteropancreatic neuroendocrine tumors?

Medically reviewed by Last updated on Feb 16, 2024.

Official answer


Lutathera (lutetium Lu 177 dotatate), a Lu-177-labeled somatostatin analogue, is a radioactive drug that binds to a somatostatin receptor on the gastroenteropancreatic neuroendocrine tumor to exert its cancer-killing effect.

The FDA approved Lutathera for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in January 2018. GEP-NETs are rare cancers that form in the pancreas, stomach, intestines, colon and rectum.

Drug information

Related support groups